The potential therapeutic possibilities of targeting lymphangiogenic factors in breast cancer using VEGFR-3 antagonists [45,46], COX-2 antagonists [47], IL-7 antagonists [48] and others have been the subject of recent intense investigation [49]. This evidence concerns the gene FLT4 and breast carcinoma.